Introduction
The multitude of cell death mechanisms identified to date include the Fas/Fas ligand (FasL) system. Fas (1,2) is a member of the tumor necrosis factor (TNF) receptor family. After ligation and oligomerization by FasL, Fas recruits the Fas-associated death domain protein through interaction mediated by their respective death domains. Fasassociated death domain protein recruits caspase-8 and induces mitochondrial permeability transition (3) through voltage-dependent anion channel (VDAC) proteins. Bcl-2 family proteins, such as Bid and BAK, bind to VDAC proteins and regulate the mitochondrial membrane potential (4) . Increased mitochondrial membrane permeability leads to the release of cytochrome C into the cytosol, which subsequently binds to dATP and Apaf-1, enabling engagement and activation of procaspase-9. Upon recruitment to the apoptosome, procaspase-3 is activated and, together with other downstream proteases, induces cell death that is termed apoptosis. VDAC proteins constitute the major pathway for metabolic exchange across the mitochondrial outer membrane. The existence of three mammalian isoforms (VDAC1, VDAC2 and VDAC3) suggests that they may each have some distinct physiological role. VDAC2 selectively prevents BAK activation and inhibits the mitochondrial apoptotic signal (5) .
The Fas/FasL system is associated with the cytotoxic mechanism of immune cells. Some Fas-positive tumor cells are killed via the stimulation of Fas by FasL on activated T cells. The loss of Fas expression results in immune escape of tumor cells. In addition to tumor cells, activation-induced FasL expression and the engagement of Fas on activated T cells are responsible for activation-induced cell death of T cells themselves. T-cell activation was also shown to cause sensitization to Fas-mediated apoptosis (6) (7) (8) (9) (10) (11) .
Previously, we developed a monoclonal anti-Fas antibody, 2D1, which is capable of inducing apoptotic cell death. The Fas-sensitive T-leukemia lines Jurkat and SUP-T13 were cultured with the anti-Fas antibody, and stable Fas-resistant variant clones, Jurkat-FasR and SUP-T13-FasR were established after limiting dilution (12) . These variant cells demonstrated phenotypes identical to those of the original cells, including cell surface Fas expression and antiapoptotic Bcl-2 protein expression. The Fas-resistant cells were as sensitive as the original cells to other apoptosis-inducing stimuli such as stimulation with c-irradiation and calcium ionophore A23187.
To determine the molecular mechanism of Fas resistance of these variant cells, we performed comparative gene expression analysis using a DNA microarray to examine the differences in gene expression between Fas-sensitive clones and Fas-resistant clones. Among the genes that were overexpressed in Fas-resistant clones, esophageal cancer-related gene 4 (ECRG4) encoded a transmembrane protein that contained a porin/VDAC-like structure. ECRG4 was previously identified as one of the downregulated genes in esophageal cancer tissues (13) . Therefore, we focused on the subcellular localization and function of ECRG4 in Fas-induced apoptosis. ECRG4 was detected in the mitochondria and endoplasmic reticulum. Overexpression of ECRG4 in Fas-sensitive Jurkat cells and RNA interference-mediated knockdown of ECRG4 in Fas-resistant Jurkat cells revealed a suppressive function of ECRG4 in Fas-induced apoptosis. Our study shows for the first time a novel function of ECRG4 in negative regulation of caspase-8-mediated apoptosis and suggests the involvement of this gene in the sensitivity of human T cells to activation-induced cell death.
Materials and methods

Cell lines and culture conditions
Human embryonic kidney cell line 293T cells were cultured in Dulbecco's modified Eagle's medium (Sigma-Aldrich, St. Louis, MO) with 10% heatinactivated fetal bovine serum and with 100 U/ml penicillin G and 100 lg/ml streptomycin. Jurkat and SUP T-13 cells were maintained in culture in RPMI 1640 (Sigma-Aldrich) supplemented with 10% fetal bovine serum, 100 U/ml penicillin G and 100 lg/ml streptomycin and were maintained at 37°C in a humidified 5% CO 2 atmosphere. The Fas-resistant Jurkat variant clone and Fas-resistant SUP T-13 variant clone were established and characterized previously (12) . All of these cells were cultured at 37°C in a humidified 5% CO 2 atmosphere.
DNA microarray analysis
Total RNA was isolated from cultured cells by using an RNeasy Mini Kit (Qiagen, Valencia, CA) and treated with DNase I (Qiagen). Cy3-and Cy5-labeled amino-allyl amplified RNAs were prepared from the purified RNA by using an amino-allyl RNA amplification kit (Sigma-Genosys, Japan) according to the manufacturer's protocol. The labeled antisense RNAs were hybridized to high-density oligonucleotide arrays (Panorama Human Microarray; SigmaGenosys) covering $29 000 genes, and the fluorescence levels were analyzed using a Genepix 4000B (Axon Instruments).
Reverse transcription-PCR and quantitative PCR
A set of complementary DNAs (cDNAs) from normal human adult tissues (multiple tissue cDNA panels) was purchased from Clontech (Palo Alto, CA).
The cDNA mixture was synthesized by reverse transcription using SuperScript III and oligo(dT) primer (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. For detection of messenger RNA (mRNA) expression, reverse transcription-PCR (RT-PCR) was performed as follows. Briefly, PCR amplification was done in a 25 ll PCR mixture containing 1 ll of the cDNA, 1 ll of KOD Dash DNA polymerase (Toyobo, Osaka, Japan) and 200 pmol primers. The PCR mixture was initially incubated at 94°C for 5 min followed by 30 cycles of denaturation at 94°C for 30 s, annealing at 60°C for 2 s and extension at 74°C for 30 s. For specific detection of ECRG4, RT-PCR analysis was performed using the primer pair 5#-AAACGAGAAGCACCTGTTCC-3# and 5#-GTAGTTGACGCTGGCTCCAT-3# as forward and reverse primers, respectively. As an internal control, GAPDH was detected by using the forward primer 5#-CGAGATCCCTCCAAAATCAA-3#and reverse primer 5#-GTCTTCTGGGTGGCAGTGAT-3#. Real-time PCR was performed using an ABI-PRISM 7900 according to the protocol of the manufacturer (Applied Biosystems, Foster City, CA). Target gene expression was calculated using DDCT and comparative methods after normalization to GAPDH expression.
Tissue samples
Tissue specimens were obtained from patients who underwent surgery at Kushiro City General Hospital. Tumor tissues and corresponding normal tissues were frozen at À80°C. Patients and their families gave informed consent for the use of tissue specimens in research.
Plasmids and transfection
To construct expression plasmids, total RNA was extracted from the Fas-resistant Jurkat clone, and cDNA was synthesized from the RNA by reverse transcription. Full-length ECRG4 with an N-terminal myc epitope tag was amplified by using specific forward and reverse primers including NheI and XhoI restriction sites. The PCR product was purified and cloned into mammalian expression vector pcDNA3.1 (Invitrogen). Full-length ECRG4 with a C-terminal flag epitope tag was amplified by using specific forward and reverse primers including BamHI and XhoI restriction sites and cloned into mammalian expression vector pcDNA3.1. Similarly, the PCR product of full-length ECRG4 with a C-terminal flag epitope tag was produced and cloned into XhoI and BamHI restriction sites of the pIRES-EGFP2 vector (Clontech). The resulting pIRES-EGFP2-ECRG4 flag was digested with Nhe I and BamHI, and the cDNA fragment was cloned into vector pIRESpuro3 (Clontech). Similarly, full-length ECRG4 was amplified by using specific forward and reverse primers including XhoI and HindIII restriction sites and cloned into pEGFP-N1 (Clontech). 293T cells and HeLa cells were transfected by using Lipofectamine 2000 reagent (Invitrogen). For stable transfection, Jurkat cells were transfected with plasmid pIRESpuro3-ECRG4 by using a Cell Line Nucleofector Kit V (Amaxa Biosystems). Two days after the transfection, transfected cells were selected in a medium containing 1.0 lg/ml puromycin.
Confocal laser microscopy
The method for confocal laser microscopy was described previously (14) . After transfection with plasmid pEGFP-N1-ECRG4, which encoded ECRG4-EGFP fusion protein, HeLa cells were cultured on a glass coverslip (Fisher Scientific, Pittsburgh, PA), fixed in 4% paraformaldehyde and permeabilized in 0.1% Triton X-100. After blocking of cells with 3% bovine serum albumin for 1 h at room temperature, the cells were incubated with a monoclonal anti-KDEL antibody (Stressgen Bioreagents, Victoria, Canada), anti-golgin-97 antibody (Molecular Probes), mitotracker (Molecular Probes) or anti-b-actin antibody (Clone AC-15; Sigma) to detect the subcellular localization of ECRG4 protein. After washing with phosphate-buffered saline (PBS), cells were immunostained with rhodamine-conjugated anti-mouse IgG antibodies (KPL, Gaithersburg, MD), followed by visualization using a confocal laser microscope (Pascal; Carl Zeiss, Tokyo, Japan).
Cell proliferation assay
Cell proliferation was assessed by using an assay based on cleavage of tetrazolium salt WST-1 to formazan by cellular mitochondrial dehydrogenases. With this assay, a change in the number of viable cells results in a change in overall activity of the mitochondrial dehydrogenases in the sample. Augmentation of the enzyme activity leads to an increase in the amount of formazan dye formed. The formazan dye formed was quantified by using a plate reader. Briefly, cells were suspended at a concentration of 0.5-2 Â 10 4 cells in 100 ll of culture medium per well on 96-well flat-bottom plates (Corning, NY) for 24-96 h. Apoptosis was induced by incubating cells with various concentrations of anti-Fas antibody CH11 (MBL, Japan), TNF alpha (Wako, Japan), Etoposide (Sigma) or staurosporine (Wako) for 24 h. Then a 1/10 volume of Premix WST-1 (Takara) was added to each well and the plates were incubated at 37°C for 2-4 h. The optical density of each well was quantified by using a microplate reader (Model 680 microplate reader, Bio-Rad). The test wavelength was 450 nm and the reference one was 655 nm.
Annexin-V labeling assay and detection of changes in mitochondrial membrane permeability First, 1 Â 10 6 Jurkat-pIRESpuro3-ECRG4 cells and Jurkat-pIRESpuro3 cells were plated on six-well tissue culture dishes with complete medium. Apoptosis was induced by incubating cells with various concentrations of anti-Fas antibody CH11 (MBL). Following the induction of apoptosis, apoptotic cells were labeled with an Annexin-V-FLUOS Staining kit (Roche Diagnostics). Briefly, the cell pellet was washed with PBS and resuspended in 100 ll of a staining solution containing Annexin-V-FLUOS and propidium iodide. After 15 min incubation at room temperature, cells were analyzed by using a fluorescenceactivated cell sorter (FACS Calibur and Cell Quest software; BD Biosciences). For detection of changes in mitochondrial transmembrane potential, the MitoCapture TM Mitochondrial Apoptosis Detection Kit (MBL) was used. Briefly, 1.5-5 Â 10 5 cells were pelleted following drug treatment and resuspended in 1 ml of prewarmed incubation buffer and 1 ll of MitoCapture. The cells were then incubated at 37°C in a humidified 5% CO 2 atmosphere for 15 min, pelleted, resuspended in 1 ml of incubation buffer and analyzed by flow cytometry.
Small interfering RNA-mediated knockdown of endogenous ECRG4 Synthetic ready to use small interfering RNA (siRNA) (21 nucleotides, stealth RNAi) and stealth RNAi negative control were purchased from Invitrogen. Small interfering RNA was introduced into Jurkat and Jurkat-FasR by using Nucleofector Device (Amaxa Inc.) and Cell Line Nucleofector Kit V (Amaxa) according to the manufacturer's protocol.
Western blotting
Cultured cells were washed in ice-cold PBS, homogenized in ice-cold radioimmunoprecipitation assay buffer (150 mmol/l NaCl, 1.0% NP40, 0.5% deoxycholic acid, 0. ECRG4 is a novel inhibitor of Fas-induced apoptosis SDS-polyacrylamide gel electrophoresis. The proteins were transferred electrophoretically to polyvinylidene fluoride membranes (Immunobilon-P; Millipore, Billerica, MA). The membranes were incubated with blocking buffer (5% nonfat dry milk in PBS) at room temperature and then incubated for 60 min with the following monoclonal antibodies (mAbs): mouse anti-Flag mAb m2 (Sigma-Aldrich), mouse anti-myc mAb 9E10, mouse anti-caspase-8 mAb 12F5 (Invitrogen), rabbit anti-Bid Ab (Abcam, UK) and mouse anti-b-actin mAb AC-15 (Sigma-Aldrich). After washing three times with wash buffer (0.1% Tween 20, PBS), the membranes were reacted with a peroxidase-labeled secondary antibody (peroxidase-labeled goat anti-mouse IgG or anti-rabbit IgG; KPL) for 30 min. Finally, the signal was visualized by using an enhanced chemiluminescence detection system (Amersham Life Science, Arlington Heights, IL) according to the manufacturer's protocol.
Caspase activity assay First, 3 Â 10 6 Jurkat-pIRESpuro3-ECRG4 cells and Jurkat-pIRESpuro3 cells were plated on six-well tissue culture dishes with complete medium. Apoptosis was induced by incubating cells with 100 ng/ml of anti-Fas antibody CH11 (MBL). The activities of caspase-8 or -3 were measured by using a APOPCYTO Caspase-8 or -3 Colorimetric Assay Kit (MDL) according to the manufacturer's protocol. Briefly, 3 Â 10 6 cells were collected, resuspended in ice-cold cell lysis buffer and incubated on ice for 10 min. Then 50 ll of reaction buffer containing 10 mM dithiothreitol was added to each well of a 96-well microplate, followed by incubation at 37°C for 4 h with 5 ll of caspase-8 substrate IETD-pNA or caspase-3 substrate DEVD-pNA. The absorbance at 405 nm was measured by using a microplate reader.
Immunoprecipitation assay 293T cells were washed, pelleted and resuspended in a lysis buffer supplemented with protease inhibitors (10 mM N-2-hydroxyethylpiperazine-N#-2-ethanesulfonic acid, pH 8.0, 150 mM NaCl, 1% 3-[(3-Cholamidopropyl)dimethylammonio]-propanesulfonate, protease inhibitor cocktail). The cell lysate was precleaned, and the supernatant was incubated for 3 h with anti-FLAG or anti-procaspase-8 (Upstate, NY) on a rotation platform at 4°C, followed by incubation with protein G-sepharose beads (GE Healthcare). Beads were collected, washed and resuspended in an equal volume of SDS sample buffer. The beads were boiled for ÃÃ P , 0.01, unpaired t-test.
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5 min with SDS sample buffer and then separated by 12.5% or 15% SDSpolyacrylamide gel electrophoresis. The western blot assay was performed as described above using appropriate antibodies.
Statistical analysis
Statistical differences between groups were evaluated using a two-tailed Student's t-test or one-way analysis of variance as appropriate, with P values ,0.05 considered significant.
Results
Comparative (Figure 1a) .
Expression of ECRG4 mRNA in normal tissues, tumor tissues and lymphocytes To elucidate the distribution of ECRG4, we investigated the expression profile of ECRG4 in normal human adult tissues. ECRG4 mRNA expression was detected ubiquitously in normal adult tissues (Figure 2a) . Since a previous report showed that ECRG4 was downregulated in cancerous tissues in the esophagus compared with its expression level counterpart normal esophageal mucosa, the expression of ECRG4 mRNA was determined in several pairs of tumor tissues and corresponding normal tissues derived from surgical specimens of the same patient (one esophageal cancer, four stomach cancers, four colon cancers, two liver cancers and two kidney cancers). ECRG4 mRNA expression was downregulated in 11 of the 13 tumor tissues (Figure 2b ). The data were basically compatible with a previous report (13) . Since ECRG4 was upregulated in Fas-resistant Jurkat cells, we investigated the expression of ECRG4 in immunocytes in both resting and activated states. RT-PCR and real-time PCR showed that ECRG4 was expressed in peripheral blood mononuclear cells, CD4-positive T cells, CD8-positive T cells and CD19-positive B cells in a resting state; however, ECRG4 was downregulated in those cells in an activated state (Figure 2c and d) .
Domain structure of ECRG4 protein ECRG4 was previously identified as one of the downregulated genes in esophageal cancer cells (13) . However, the function of ECRG4 has not been elucidated yet. To examine the function of ECRG4, we performed a homology domain search by using a public protein structure database. Analysis using the SMART database (http://smart. embl-heidelberg.de/) revealed that ECRG4 had one transmembrane segment starting at amino acid position 10 and ending at amino acid position 32 (Figure 1c, italics) . By analysis using the BLOCKS database (http://bioinfo.weizmann.ac.il/blocks/blocks_search.html), it was further revealed that ECRG4 contained a porin/VDAC homology domain (amino acids 111-140), a cell division cycle 45 (Cdc45) homology domain (amino acids 64-91) and an anaphase-promoting complex subunit 10 (APC 10) homology domain (amino acids 54-104) (Figure 1b) . The amino acid sequence of the VDAC homology domain of ECRG4 (Figure 1c , underlined bold face) is aligned with that of VDAC2 in Figure 1d . The amino acid sequence of the VDAC homology domain of ECRG4 showed significant homology with that of VDAC2 (28% identity [9/32 amino acids] and 50% similarity [16/32 amino acids]) (Figure 1d ). The structural characterization indicated that ECRG4 might be a transmembrane protein that is associated with mitochondrial membrane permeability and cell cycle.
Subcellular localization of ECRG4
To determine the subcellular localization of ECRG4, an expression plasmid encoding ECRG4-EGFP fusion protein was introduced into HeLa cells, and the fusion protein was detected by confocal laser microscopy. Subcellular organelles were visualized by immunofluorescence staining with antibodies against organelle-specific markers such as the mitochondria marker MitoTracker Red 580, Golgi apparatus marker golgin-97, endoplasmic reticulum marker amino acid 
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sequence KDEL and cytoskeletal marker b-actin. The confocal laser microscopy showed that ECRG4 was colocalized with MitoTracker Red 580, anti-golgin-97 Ab and anti-KDEL Ab but not with antib-actin Ab in HeLa cells (Figure 3a-d) . These findings indicated that ECRG4 was localized in the mitochondria, Golgi apparatus and endoplasmic reticulum.
ECRG4-expressing Jurkat cells acquired resistance to Fas-induced apoptosis ECRG4 was upregulated in apoptosis-resistant Jurkat FasR cells and SUP T-13-FasR cells, and it was expressed in resting immunocytes, which are resistant to apoptosis. And part of ECRG4 protein is localized to mitochondria which has role in induction of apoptosis. Therefore, we further investigated ECRG4 roles in apoptosis. To determine whether the increased ECRG4 levels conferred resistance to Fas-induced apoptosis in Jurkat cells, we established stable Next, the sensitivity to Fas stimulation was compared among parental Jurkat cells, Jurkat mock cells and Jurkat ECRG4 cells. The cell viability was assessed by WST-1 assay and apoptotic cell death rate was assessed by annexin-V/propidium iodide-labeling assay, respectively. In the WST-1 assay, Jurkat ECRG4 cells showed a significantly higher survival rate at various concentrations of the anti-Fas antibody than the survival rates of parental Jurkat cells (Jurkat-WT) and Jurkat mock cells (Figure 4a ). In the annexin-V/propidium iodide-labeling assay, the percent of cells showing annexin-V was less for Jurkat ECRG4 cells than for Jurkat mock cells (Figure 4b ). These observations indicate that Jurkat ECRG4 cells are resistant to apoptosis by Fas stimuli.
Expression of ECRG4 inhibits mitochondrial membrane permeability transition Since ECRG4 was estimated to contain a VDAC homology domain and it was localized on mitochondria, we investigated whether ECRG4 expression could affect mitochondrial membrane depolarization and permeability. MitoCapture, a cationic dye, provides a fluorescencebased molecular probe for detecting changes in mitochondrial Figure 2A , available at Carcinogenesis Online). These findings indicated that ECRG4 expression inhibited apoptosis through suppressing mitochondrial membrane depolarization and permeability.
Knockdown of endogenous ECRG4 increases sensitivity to Fas-mediated apoptosis
To confirm the antiapoptotic function of ECRG4, we investigated whether decreases in endogenous ECRG4 levels alter the sensitivity to Fas-mediated apoptosis. Since an anti-ECRG4 antibody was not available for detection of endogenous ECRG4 protein, we assessed the efficacy of RNA interference by RT-PCR. We tested three different siRNA duplexes designed to target ECRG4 and confirmed that ECRG4-specific siRNA2 was the most effective in decreasing endogenous ECRG4 mRNA level in Jurkat FasR cells (Supplementary Figure 3A , available at Carcinogenesis Online). After culture of siRNA transfected cells in media containing various concentrations of anti-Fas antibodies for 48 h, live cell rates were assessed by the WST-1 assay. It was shown that knockdown of endogenous ECRG4 mRNA leads to decreases in survival rate after Fas stimulation of Jurkat FasR cells (Supplementary Figure 3B , available at Carcinogenesis Online). After culture of siRNA transfected cells in a medium containing 100 ng/ml anti-Fas antibody for 1 h, early apoptotic cells with increased mitochondrial membrane permeability were assessed by the MitoCapture assay. It was shown that knockdown of endogenous ECRG4 increases the sensitivity to Fas-mediated alterations of mitochondrial membrane depolarization in Jurkat FasR cells (Supplementary Figure 3C , available at Carcinogenesis Online), suggesting that ECRG4 is involved in the negative regulation of Fas-induced apoptotic signals, at least in part, at the level of mitochondria or the upstream level of mitochondria in Jurkat cells.
Overexpression of ECRG4 suppresses TNF-alpha-induced apoptosis in Jurkat cells
ECRG4 has a suppressive role in apoptosis induced by Fas probably by inhibiting mitochondrial membrane depolarization and permeability, we extended our focus to other apoptosis stimuli including TNFalpha, etoposide and staurosporine. Sensitivity to apoptotic stimuli was assessed by the WST-1 assay. Jurkat ECRG4 cells showed a significantly higher survival rate at various concentrations of TNF-alpha than that of Jurkat mock cells (Figure 5a ). Etoposide, a well-known cancer chemotherapeutic agent, is an inhibitor of topoisomerase II and induces p53-dependent apoptosis (15) . Jurkat-ECRG4 and control cells showed almost identical sensitivities to etoposide-induced apoptosis (Figure 5b ). Staurosporine is a protein kinase inhibitor and induces apoptosis independently of caspase-8 activation (16) . Jurkat ECRG4 and control cells showed almost identical sensitivities to staurosporine-induced apoptosis (Figure 5c ). These results indicated that ECRG4 suppresses caspase-8-dependent apoptosis but does not suppress caspase-8-independent apoptosis.
Overexpression of ECRG4 suppresses the activity of caspase-8 To elucidate the exact molecular mechanism by which ECRG4 suppresses caspase-8-mediated apoptosis, the following experiments were performed. Bid is known as a proapoptotic molecule (17) that functions upstream of mitochondria in caspase-8-dependent apoptotic signals (18) . To determine the intracellular signaling events in ECRG4-expressing cells, we examined cleavage of caspase-8 and Bid in Jurkat ECRG4 cells after stimulation with anti-Fas mAb. As shown in Figure 6a , cleaved caspase-8 subunit p18 was detected at similar levels in ECRG4 transfectants and mock control cells; however, truncated Bid was not detected in ECRG4-expressing Jurkat cells. Next, we examined activities of caspase-8 in Jurkat transfectant cells after stimulation with anti-Fas mAb. The activities of caspase-8 were significantly suppressed in ECRG4-expressing Jurkat cells (Figure 6b) . Immunoprecipitation results demonstrated that ECRG4 was associated with procaspase-8 ( Figure 6c) but not with Bid (data not shown). The results clearly show that ECRG4 can be associated with procaspase-8 and suppress the activity of caspase-8, thus leading to the suppression of Fas-induced apoptosis.
Discussion
We identified and characterized a novel antiapoptotic molecule, ECRG4, which was aberrantly expressed in Fas-resistant T-cell variant clones. The ECRG4 gene was previously cloned from human normal ÃÃ P , 0.01, unpaired t-test.
ECRG4 is a novel inhibitor of Fas-induced apoptosis esophageal epithelium and identified as one of the downregulated genes in esophageal squamous cell carcinoma tissues (13) . The mechanism of gene inactivation in tumor tissues involves DNA methylation, and it is a frequent molecular event in esophageal squamous cell carcinoma (13) . It was reported that low-ECRG4 mRNA expression levels were associated with significantly short survival after surgery compared with high-ECRG4 mRNA expression levels in esophageal cancer patients (19) . Therefore, it has been speculated that ECRG4 is a tumor suppressor gene that is frequently inactivated in esophageal cancer cells. ECRG4 is also known as a senescence inducer (20) . Cell senescence is defined as irreversible growth arrest. It acts as a potent barrier to tumorgenesis in vivo. In senescent cells, there is increased sensitivity with advance of age to the intrinsic pathway that regulates apoptosis. This sensitivity includes increased cell death in response to ultraviolet light, radiation, stress and other toxins. In contrast, there is generally an age-related decrease in apoptosis mediated through the extrinsic pathway. The extrinsic pathway is signaled through TNF receptor superfamily members, including Fas. A key regulator of apoptosis signals that operates within the intrinsic pathway is p53, whereas a key regulator of apoptosis signals that operates within the extrinsic pathway is caspase-8 (21). However, little is known about the function of ECRG4 in apoptosis.
In the present study, we examined the expression and function of ECRG4. Caspases are cysteine proteases that play a central role in apoptotic signals. Caspase-8 is the most upstream caspase in the proteolytic cascade that is activated by Fas ligand and TNF-alpha. During Fas-mediated apoptosis, procaspase-8 is recruited to the death-inducing signaling complex. Procaspase-8 is first cleaved into intermediate cleavage products and is subsequently processed to p18 subunits and p10 subunits. The heterodimer of p18 and p10 subunits is the active form of caspase-8. The active form of caspase-8 cleaves Bid, and the C-terminal part translocates to mitochondria, where it triggers cytochrome C release. While full-length BID is localized in the cytosol, truncated Bid translocates to mitochondria and thus transduces apoptotic signals from the cytoplasmic membrane to mitochondria.
FLICE inhibitory protein interacts with caspase-8 through distinct domains and suppresses Fas-induced apoptosis (22) . Our data showed that ECRG4 also associated with procaspase-8 and suppressed the activation of caspase-8, leading to inhibition of the cleavage of Bid. Procaspase-8 is a precursor of caspase-8 and is also the full length of caspase-8. ECRG4 is associated with procaspase-8, which is the full length of caspase-8; however, the ECRG4-binding site in the full length of caspase-8 remains unclear. Since ECRG4 did not affect the cleavage of p18 subunits of caspase-8, it might inhibit the configuration of the active conformation of caspase-8.
ECRG4 contains a VDAC2-like domain that might be associated with apoptotic signals. Procaspase-8 localizes in both the mitochondria and the cytosol; however, active caspase-8 is localized in mitochondria by apoptotic stimulations (23) . A native complex containing caspase-8 and Bid localized on the mitochondrial membrane and death receptor activation by Fas induced the cleavage of Bid within this complex. tBid then shifted to separate mitochondrial-associated complexes that contained other Bcl-2 family members, such as BAK and Bcl-xL (24) . Our data showed that ECRG4 was also localized in mitochondria, suggesting that ECRG4 inhibits caspase-8 activation on the mitochondrial membrane, suppresses cleavage of Bid and leads to inhibition of the mitochondrial apoptosis pathway. VDAC2 is associated with BAK, leading to prevention of BAK activation and inhibition of the apoptosis pathway (5). Therefore, ECRG4 inhibited apoptosis at the upstream level of VDAC2 in the mitochondrial apoptosis signaling.
Our data revealed that ECRG4 is involved in the suppression of Bid cleavage and subsequent mitochondrial membrane permeability transition induced by Fas stimulation. Thus, ECRG4 may have an antiapoptotic function similar to that of VDAC2 on the mitochondrial outer membrane. It was noted that ECRG4 was localized not only to mitochondria but also to the endoplasmic reticulum and Golgi apparatus. Since it has been proposed that VDAC1 and the Bcl-2-family also reside and function in extramitochondrial membranes including the endoplasmic reticulum (25) , ECRG4 may be involved in various cellular functions in multicompartment localization in concert with VDAC1 and the Bcl-2 family.
Our results and results of other studies show that ECRG4 expression is decreased in tumor tissues. Therefore, the antiapoptotic function of ECRG4 cannot explain the significance of ECRG4 in tumorigenesis. In this context, ECRG4 contains a CDC45-and APC10 homology domain, and ECRG4 expression inhibits the growth of various tumor cells (data not shown). It is possible that ECRG4 has both an antiapoptotic function and an antiproliferative function as reported for Bcl-2 family proteins (14, (26) (27) (28) . Besides the role of ECRG4 in tumorigenesis, it should be noted that ECRG4 might be involved in the development and fate of normal T cells. ECRG4 is expressed in peripheral resting T cells, but it is downregulated after their activation. The expression of ECRG4 may be associated with survival potential of naive T cells, and its downregulation after activation may be associated with activation-induced cell death mediated by Fas/ FasL stimulation in both mature and immature T cells.
In conclusion, we have identified and characterized an antiapoptotic function of ECRG4. ECRG4 was found to be localized in the mitochondria, endoplasmic reticulum and Golgi apparatus. ECRG4 has a function of suppressing Fas-induced apoptosis through inhibition of ) were plated on a culture dish. Apoptosis was induced by incubating cells with 100 ng/ml anti-Fas antibody CH11 for the indicated time. Following induction of apoptosis, the activities of caspase-8 were measured by using a APOPCYTO Caspase-8 Colorimetric Assay Kit. Data represent the averages of triplicate samples and the standard deviation compared with control cell activities.
ÃÃ P , 0.01, unpaired t-test. (c) 293T cells were transfected with FLAG-tagged ECRG4 and procaspase-8, mock and procaspase-8 (control). Co-immunoprecipitation assay was performed using anti-FLAG, anti-procaspase-8 and without antibody (beads only). Immunoprecipitation assay demonstrated that ECRG4 is associated with procaspase-8.
